



LUND UNIVERSITY

Aspects on optimisation of High Dose Methotrexate treatment in children with Acute Lymphoblastic Leukaemia

Jönsson, Peter

2008

[Link to publication](#)

Citation for published version (APA):

Jönsson, P. (2008). *Aspects on optimisation of High Dose Methotrexate treatment in children with Acute Lymphoblastic Leukaemia*. [Doctoral Thesis (compilation), Division of Clinical Chemistry and Pharmacology]. Clinical and Experimental Pharmacology, Lund University.

Total number of authors:

1

General rights

Unless other specific re-use rights are stated the following general rights apply:

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

Read more about Creative commons licenses: <https://creativecommons.org/licenses/>

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

LUND UNIVERSITY

PO Box 117
221 00 Lund
+46 46-222 00 00



Childhood Acute Lymphoblastic Leukaemia (ALL) has a unique place in the history of oncology, as it was the first cancer to be cured by drugs. It is therefore an important model upon which concepts of chemotherapy in other malignancies have been developed. Methotrexate is a major component of most contemporary childhood ALL treatment protocols.

The main objectives of this thesis were to investigate how methotrexate concentration time data from high dose methotrexate intravenous infusions relate to renal toxicity, to investigate how methotrexate concentrations in the cerebrospinal fluid are related to systemic levels and risk of a central nervous system (CNS) relapse, to build a population pharmacokinetic model from

methotrexate concentration time data and assess how pharmacokinetic parameter predict relapse risk.

An increase in serum creatinine of more than 50% could identify individuals with a delayed elimination of methotrexate whereas markers of tubular function were not related to a delayed elimination of methotrexate. A relationship between cerebrospinal fluid (CSF) and systemic concentrations was described with statistics that handle both the inter- and intra patient variability. Applying this relationship to a larger population suggests that increased CSF methotrexate concentrations are related to a decreased risk of a CNS relapse. Using a population pharmacokinetic model body weight was found to give a better model fit to the data than body surface area. Thus, a dose calculated from body weight may result in more predictable methotrexate concentrations. Patients with an increased clearance and volume of distribution had an increased risk of relapse. Pharmacokinetic parameters adjusted for body weight were, however, not significantly correlated to relapse risk. This further indicates that body weight is a preferred anthropomorphic measurement for dose modification of high dose methotrexate intravenous infusions in childhood ALL.

The clinical value of these findings should be evaluated in prospective, controlled clinical trials before they are put into clinical practice.



LUND UNIVERSITY
Faculty of Medicine

Lund University, Faculty of Medicine Doctoral Dissertation Series 2008:75
ISSN 1652-8220
ISBN 978-91-86059-28-6

Aspects on optimisation of High Dose Methotrexate treatment in children with Acute Lymphoblastic Leukaemia

Peter Jönsson

Clinical and Experimental Pharmacology
Lund University, 2008

